Zacks Research Issues Positive Estimate for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Monday, May 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings of ($1.20) per share for the quarter, up from their previous forecast of ($1.27). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($3.97) EPS, Q1 2026 earnings at ($0.59) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at ($0.78) EPS, Q1 2027 earnings at $0.43 EPS and FY2027 earnings at $4.54 EPS.

Other equities analysts have also issued reports about the company. Robert W. Baird upped their target price on Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft started coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the company an "outperform" rating in a research note on Tuesday, April 29th. Leerink Partners boosted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, February 10th. Finally, Morgan Stanley upped their price target on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $172.14.

Axsome Therapeutics Stock Performance

Shares of NASDAQ:AXSM traded up $0.28 during trading on Thursday, hitting $104.92. 485,793 shares of the company traded hands, compared to its average volume of 687,208. The stock has a market capitalization of $5.17 billion, a price-to-earnings ratio of -17.52 and a beta of 0.46. The business's fifty day moving average is $106.72 and its 200-day moving average is $106.09. Axsome Therapeutics has a one year low of $64.11 and a one year high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22.

Insider Activity

In related news, COO Mark L. Jacobson sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $103.45, for a total value of $2,069,000.00. Following the completion of the transaction, the chief operating officer now owns 5,783 shares in the company, valued at $598,251.35. The trade was a 77.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mark Coleman sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $107.49, for a total transaction of $322,470.00. Following the completion of the transaction, the director now owns 54,137 shares of the company's stock, valued at $5,819,186.13. This trade represents a 5.25% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,423 shares of company stock worth $4,950,619. Insiders own 22.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers grew its holdings in Axsome Therapeutics by 6.9% during the 1st quarter. Rhumbline Advisers now owns 54,760 shares of the company's stock worth $6,387,000 after acquiring an additional 3,515 shares during the period. Strs Ohio acquired a new stake in Axsome Therapeutics during the 1st quarter worth $1,213,000. McAdam LLC acquired a new stake in Axsome Therapeutics during the 1st quarter worth $256,000. Intech Investment Management LLC grew its holdings in Axsome Therapeutics by 26.6% during the 1st quarter. Intech Investment Management LLC now owns 20,298 shares of the company's stock worth $2,367,000 after acquiring an additional 4,270 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company's stock worth $8,735,000 after acquiring an additional 17,250 shares during the period. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.